SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) hosted the Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches during the 39^th Annual Meeting & Pre-Conference Programs on November 6, 2024. Available here are the presentation slides and video from “Session 1: Emerging – What's Next – Promising New Modalities” as permitted by presenters.

Program Organizers

• Nicholas Botwood, MD – Bristol Myers Squibb
• Ivan Diaz-Padilla, MD, PhD  – GSK
• Charles G. Drake, MD, PhD  – Johnson and Johnson Innovative Medicine
• Jane Anne Healy, MD, PhD  – Merck Sharp & Dhome LLC
• Priti Hegde, PhD  – Kite Pharma 
• Stephen Lim, MD  – Novartis 
• Giovanni Melillo, MD  – AstraZeneca

Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.

Program Description

The SITC 2024 Industry Program, “Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches,” will advance the science and application of cancer immunotherapy by bringing together some of the top experts in industry and academia to provide high-level clinical and scientific perspectives surrounding new, emerging modalities of cancer immunotherapy. The program will explore promising new modalities of cancer immunotherapy, applications of these modalities in the clinical setting, and preclinical and translational studies of future applications of these modalities, including studies surrounding patient selection and indicators of response or resistance. The program will also address clinical and scientific considerations combining these modalities with other cancer therapies. Armed with a deeper understanding of the clinical and scientific information around the newest modalities of cancer immunotherapy, attendees will be better equipped to develop and utilize cancer immunotherapy-based treatment strategies that are cost-efficient, safer, and more effective for patients.

Learning Objectives

At the conclusion of this activity, participants should be able to: 

• Summarize recent clinical development of new modalities of cancer immunotherapies, specifically immune cell engagers, adoptive cellular therapies, and antibody-drug conjugates
• Discuss ongoing preclinical and translational studies of these new modalities and their relevance to patient selection or detecting response or resistance to immunotherapy
• Address specific considerations when these new modalities are used in clinical settings as monotherapy or in combination with other cancer therapies

To view the entire program schedule (including presenter permission to post) please click here.